Lexaria Bioscience (LEXX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Lexaria Bioscience has launched a 12-week Phase 1b study to assess if its DehydraTECH technology can enhance the safety and effectiveness of GLP-1 drugs, potentially reducing side effects and improving efficacy. This study, involving various capsules and tablets, aims to provide significant insights into diabetes control and weight loss management. Conducted across seven sites in Australia, the study’s findings may align with FDA standards.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
